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Aim/Objectives: The current Scottish Intercollegiate Guidelines Network (SIGN) guidelines
recommend beta blockers and dihydropiridine calcium channel blockers as first-line agents for
refractory angina pectoris. Despite being optimally treated with pharmacotherapy and
revascularisation, up to 40% of patients still experience symptoms.
Ranolazine, a piperazine derivative, selectively inhibits late sodium currents and is of particular
interest as it is currently not recommended routinely by SIGN guidelines and Scottish Medicine
Consortium (SMC) but has been prescribed in Tayside, initially through IPTR since 2017 and
recently through a Local New Medicine Treatment Protocol and Stable Angina Pathway. Real
world experience of ranolazine prescribing in patients with chronic and often refractory
angina is not widely reported. We therefore audited its use in Tayside to understand its
prescribing pattern within our patient population and assess its effects on angina symptom
relief.
Methods: Electronic health records and prescribing data between 1st January 2012 and 31st
December 2018 were retrospectively analysed. Data on baseline characteristics, prescribing
information, past medical history, and angina symptom control were collected. Standard
descriptive statistics were used for analysis.
Results: 35 patients were identified as suitable for inclusion in the audit. Mean age was 71.4 ±
12.5 years old and 68.6% were male. 23 patients (65.7%) had either a previous percutaneous
coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). The most common
reason for ranolazine prescription was refractory angina (74.3%) with 375 mg BD being the
most common dose. Prescription of guideline-recommended anti anginals was high with 80%
of patients being on a beta blocker and a nitrate prior to commencing ranolazine.
Encouragingly, 27 patients (77.1%) reported an improvement in Canadian Cardiovascular
Society (CCS) angina class and the rate of non-responders was 22.9%. No adverse effects
leading to discontinuation of ranolazine was found.
Conclusion: Ranolazine may play a role as an additional anti anginal agent with reasonable
achievement of symptom control in patients who have refractory angina despite the use of
other guideline-recommended anti anginal agents.
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Introduction
The 2019 European Society of Cardiology
guidelines for CCS recommend the use of
ranolazine as an adjunct therapy for those
not controlled by first line treatments.1
The guidance highlights the importance of
tailoring pharmacological therapies to
patient specific characteristics and
preferences. It states that ranolazine should
be considered as a second line therapy to
reduce the number of angina episodes and
to improve exercise tolerance in those who
cannot tolerate, or their symptoms are not
controlled by, beta-blockers, calcium
channel blockers or long acting nitrates.
Additionally, ranolazine may be considered
as a first line therapy in patients with low
heart rate and blood pressure [1]. The
National Institute for Health and Care
Excellence (NICE) Stable Angina
Management Guidelines (2011) give
similar recommendations. It states that
ranolazine may be used as a monotherapy
if beta blockers or calcium channel
blockers cannot be used or tolerated. The
NICE guidance also recommends that
ranolazine may be added in addition to
beta blocker or calcium channel blocker
monotherapy if the patient’s symptoms are
not controlled and the other first line
therapy is contraindicated [2].
The Scottish Intercollegiate Guidelines
Network (SIGN) provides alternative
recommendations with regards to the use
of ranolazine in the management of stable
angina. SIGN describes the evidence
regarding ranolazine efficacy as conflicting
[3-5].
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In 2012, the Scottish Medicines Consortium (SMC) did
not approve ranolazine to be used as an add on therapy for
stable angina in those who cannot tolerate first line
therapies or who are symptomatic despite their use.
Consequently, special approval had to be requested for its
use in Scotland. This was the case in Tayside, Scotland
initially through Individual Patient Treatment Request and
latterly through a Local New Medicine Treatment Protocol
and Stable Angina Pathway. The aim of this study was to
establish the current ranolazine prescribing practices in a
large Scottish teaching hospital and to assess its impact and
tolerability within our patient cohort on angina symptom
relief.
Methods
We retrospectively analysed health records of patients who
were prescribed Ranolazine for either chronic stable angina
or refractory angina in our hospital between 1st January
2012 to 31st December 2018. As Ranolazine is not
currently recommended as an anti anginal agent by the
Scottish Medicines Consortium (SMC) therefore
prescribing was on a case by case basis. The responsible
clinician was required to complete an individualised patient
treatment request (IPTR) and to review the patient ’ s
symptoms in 4 weeks to ensure improvement in symptoms.
Patients who were prescribed ranolazine were deemed to not
be suitable for percutaneous coronary intervention/coronary
artery bypass graft surgery (CABG), or have already had
revascularisation but remained symptomatic with no further
invasive treatment options. Data on demographics,
treatment indication, and previous intervention,
concomitant anti anginal agents, Ranolazine dose, and
whether there was an improvement in Canadian
Cardiovascular Society symptoms were collected.
Descriptive statistics were displayed as mean ± standard
deviation for continuous variables and numbers and
percentages for categorical variables. This study was
approved by the local institutional review board for data
collection and analysis.
Results
35 patients were identified as suitable for inclusion in the
audit. Mean age was 71.4 ± 12.5 years old and 68.6% were
male (Table 1).
Table 1: Baseline characteristics.
Characteristic Ranolazine group(n=35)
Age, years (mean ± SD) 71.4 ± 12.5
Age of first prescription, years (mean ±
SD) 69.1 ± 12.1
Duration on Ranolazine, years (mean ±
SD) 3.0 ± 2.2
23 patients (65.7%) had either a previous percutaneous
coronary intervention (PCI) or coronary artery bypass graft
surgery (CABG) (Table 2). The most common reason for
ranolazine prescription was refractory angina (74.3%) with
375 mg BD being the most common dose (62.9%) (Table
2).
Table 2: Symptom and treatment characteristics.
Characteristic Frequency (%)
Previous PCI 19 (54.3%)
Previous CABG 10 (28.6%)
Previous CABG and PCI 6 (17.1%)
No previous CABG or PCI 12 (34.3%)
Reason for prescription
Recurrent angina 26 (74.3%)
Chronic stable angina 5 (14.3%)
No intervention options 3 (8.6%)
Part of research trial 1 (2.9%)
Concurrent medications
Beta blocker 30 (85.7%)
Nitrates 32 (91.4%)




375 mg BD 22 (62.9%)
500 mg BD 12 (34.3%)
750 mg BD 1 (2.9%)
Effect on symptoms
No change 8 (22.9%)
Improvement in CCS class 27 (77.1%)
Class II to Class I 22 (81.5%)
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Male 68.60%
4 agents 4(11.4%)
Prescription of other guideline-recommended anti anginal
agents was high with 80% of patients being on a beta
blocker and a nitrate prior to commencing ranolazine
(Table 3). Encouragingly, 27 patients (77.1%) reported an
improvement in Canadian Cardiovascular Society (CCS)
angina class and the rate of non-responders was 22.9% all of
whom eventually discontinued Ranolazine use. No adverse
effects leading to discontinuation of ranolazine was found.
Table 3: Other antianginal agents.
Combination Frequency (%)
Beta blockers and nitrates 28(80%)
Beta blockers and dihydropyridine
calcium channel blockers 9(25.7%)
Beta blockers, calcium channel
blockers, and nicorandil 3(8.6%)
Beta blockers, calcium channel
blockers, and nitrates 9(25.7%)
Beta blockers, calcium channel
blockers, ivabradine 1(2.9%)
Discussion
We report real world data on the use of Ranolazine in
patients with refractory angina and chronic stable angina
not amenable to further revascularisation. Overall, patients
in our centre were treated with good combination of
guideline directed medical therapy (GDMT) with 45.7% of
patients taking 3 other anti-anginal agents prior to the
addition of Ranolazine, reflecting judicious prescribing
practice. The majority of patients (80%) were on a beta
blocker and a nitrate. Despite this, improvement in CCS
angina class was still observed in 77.1% of patients, a
finding that is similar to previous work by Bennet et al in a
1-year prospective registry of 100 refractory angina patients
[6]. Tolerability was good as we did not find any evidence of
side effects in the 35 patients studied. The maximum dose
required was 500 mg BD in all of our patients except one.
This could of course partially explain the lack of observed
side effects.
Refractory angina is defined as angina in the setting of
coronary disease of more than 3 months ’  duration, not
adequately controlled with optimal medical therapy
(OMT), percutaneous coronary intervention (PCI) or
coronary artery bypass graft surgery (CABG) and where
reversible myocardial ischaemia has been established as the
cause of the symptoms.7 This group of patients often prove
challenging to manage and although no precise figures of
the scale of the problem is available, it is estimated that
there are around 16,500 new cases per year in England
alone [7]. This is likely to increase as coronary artery disease
(CAD)-related survival improves in an increasingly ageing
population.
The most recent European Society of Cardiology (ESC)
guidelines on management of chronic coronary syndromes
(2019) lists Ranolazine as a potential third agent of choice
in managing angina. This is largely guided by the usual
limiting factors of heart rate, blood pressure, and the
presence of concomitant left ventricular (LV) systolic
dysfunction as well as patient ’ s characteristics and
preferences. It is unclear whether combination therapy with
two agents is superior to monotherapy with any class of
drugs in reducing clinical events [8]. Beta blockers and/or
calcium channel blockers are recommended first line agents,
based on meta-analyses of RCTs without mortality
endpoints as it is widely accepted that the main focus of
stable angina treatment is symptom management rather
than achieving mortality benefit [1,9].
Ranolazine is a selective inhibitor of late inward sodium
channel current (INaL). It reduces intracellular calcium
overload during ischaemia, oxidative stress, and LV
hypertrophy with a resultant effect of improvement in
oxygen demand-supply mismatch. Although there have
been 4 randomised controlled trials focusing on Ranolazine
use instable angina patients as well as patients with acute
coronary syndrome (ACS), real world data on patients with
refractory and/or chronic stable angina is scarce [10-13].
This could partially explain the discrepancy in prescribing
practice among hospitals in the United Kingdom. Our audit
over a period of 6 years in a large teaching hospital in
Scotland with certain prescribing restrictions in place, has
provided further data to support the potential incremental
benefit of Ranolazine in addition to other GDMT anti
anginal agents in this population of patients as well as its
tolerability.
This was a retrospective audit and therefore has several
known limitations. The non-randomised nature of the data
subjects the findings to unknown residual confounders. It
was also a single-centre experience and therefore limits its
generalizability to other patient populations. Furthermore,
the lack of side effects seen could be related to the majority
of patients being on a maximum dose of 500 mg BD as the
majority of side effects are more likely to occur at the higher
end of the dose spectrum. We also did not set out to
investigate the antiarrhythmic properties of Ranolazine in
our patient population, a feature that has previously been
attributed to the use of Ranolazine [14]. Nevertheless, the
lack of side effects seen and a 77% rate of observed
improvement in CCS angina class are encouraging.
Conclusion
In a real world population of refractory angina and chronic
stable angina patients not amenable to further
revascularisation, the addition of Ranolazine to GDMT
may improve symptoms and is well tolerated.
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